This study highlights the ability of the SureSeq™ Myeloid Fusion Panel to detect multiple fusions, identify breakpoints, and capture MECOM overexpression, so your lab can achieve higher efficiency sample classification with a single assay.
Read and download the App noteFirst presented at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, this scientific poster demonstrates the capabilities of our SureSeq™ CLL + CNV V3 Panel in detecting copy number alterations and gene variants in Chronic Lymphocytic Leukemia (CLL).
Read and download the Scientific posterPresented at the 14th Annual Meeting of the Cancer Genomics Consortium, this poster demonstrates our measurable residual disease (MRD) next generation sequencing (NGS) capabilities in acute myeloid leukemia (AML) monitoring.
Read and download the Scientific posterThe aim of this study is to evaluate a modified version of the OGT™ Universal NGS Workflow Solution in conjunction with a custom SureSeq™ targeted panel for use with cfDNA.
Read and download the Scientific posterPresented at the AMP 2020 virtual meeting, this poster demonstrates the capability of the SureSeq™ Breast Cancer + CNV Panel in combination with Interpret software to detect germline and mosaic CNVs.
Read and download the Scientific posterThis technical note compares performance of CytoSure Constitutional NGS and a range of microarrays for 255 research samples processed in three independent laboratories and OGT.
Read and download the App notePresented at ESHG Virtual 2020, this poster outlines the results from over 200 intellectual disability and developmental research samples to demonstrate the efficiency of the CNV, SNV and LOH detection.
Read and download the Scientific posterPresented at ACMG 2020, this poster demonstrates the capability of a novel NGS assay designed to analyse genetic aberrations, including CNVs, SNVs, Indels and LOH, in intellectual disability and developmental delay research samples.
Read and download the Scientific posterThe primary objective of this study was to assess ctDNA clearance during neoadjuvant treatment as a correlate to effective response to treatment, as benchmarked by clinical complete response (cCR) and pathological complete response (pCR).
Read and download the Scientific posterMaking the change from microarrays to NGS is a daunting prospect, particularly when it comes to data analysis. This app note outlines some of the key features we’ve incorporated to help make the change from arrays to NGS as painless as possible.
Read and download the App notePresented at AMP 2019, this poster demonstrates how OGT’s SureSeq Interpret software shows robust and reproducible results in the detection of low-frequency variants using reference standards.
Read and download the Scientific posterPresented at AMP 2019, this poster demonstrates the capability of SureSeq CLL CNV - 14 gene panel to overcome the challenges with detecting copy number alterations (CNAs) currently experienced and provide a possible future single test to be developed for Chronic Lymphocytic Leukaemia (CLL).
Read and download the Scientific poster{{literatureDetailsPage.Summary}}
Read and download the {{literatureDetailsPage.FriendlyResorceType}}
Visit International site
Visit USA site
International
